Dec 12, 2017, Shanghai, China — Evive Biotech, an innovative biotech company in China developing novel therapeutic biologics to treat cancer and inflammatory diseases, today announced that China’s State Intellectual Property Office recently granted a patent application, titled as “Multi-Specific Fab Fusion Proteins and Methods of Use ”(patent number: ZL201280033111.1).

This patent disclosure relates to CD3 engaging bispecific antibodies produced via Evive’s Immuno-Therapy Antibody^TM platform (ITab^TM).  The ITab^TM bispecific antibodies comprise an anti-human CD3 Fab, consisting of variable and constant region components and binding domains that are targeting tumor antigens.

“The grant of this patent application by SIPO is exciting and inspiring.  We view this grant as recognition of Evive’s innovative technology in the development of bispecific antibodies for tumor immuno-therapy, further strengthening Evive’s patent portfolio” said Dr. Xiaoqiang Yan, Evive’s CEO. A related patent,US8,846,042, was issued by the US Patent and Trademark Office in Sep. 2014.   ITab^TM’s unique structure allows for a better permeability in solid tumors, with a longer half-life and improved safety window, and with robust manufacturing processes.

About ITab^TM 

Evive’s ITab^TM (immunotherapy antibody) platform generates bi-specific antibodies that bind to the CD3 molecule on human T cells, and simultaneously bind to specific tumor associated antigens (TAAs) in a mono-valent or bi-valent format. The formation of a synapse between the tumor cell and the T cell linked by the antibody leads to the activation of the T cell, and the release of mediators lysing the tumor cell. These bi-specific antibodies can drive the expansion of T cells, rendering T cells as serial killers of tumor cells. ITab^TM antibodies are manufactured in CHO cells in serum-free conditions.